Skip to main content
. 2022 Jul 25;2022:3549047. doi: 10.1155/2022/3549047

Table 5.

Comparisons of spot urine creatinine-to-osmolality ratio according to conditions of demographics, comorbidities, and medication use.

sUCr/Osm
Mean ± SD
P value
Sex
 Male vs. female 0.20 ± 0.09 vs. 0.17 ± 0.08 <0.001
Races
 Mexican American 0.17 ± 0.07 <0.001a
 Other Hispanic 0.17 ± 0.07
 Non-Hispanic White 0.18 ± 0.08
 Non-Hispanic Black 0.23 ± 0.10
 Non-Hispanic Asian 0.16 ± 0.07
 Other races 0.19 ± 0.08
 African American (yes vs. no) 0.23 ± 0.10 vs. 0.18 ± 0.07 <0.001
Comorbidities (yes vs. no)
 Hypertension 0.19 ± 0.09 vs. 0.19 ± 0.08 0.054
 Diabetes mellitus 0.18 ± 0.09 vs. 0.19 ± 0.08 0.123
 Coronary artery disease 0.20 ± 0.08 vs. 0.19 ± 0.08 0.199
 Congestive heart failure 0.21 ± 0.09 vs. 0.19 ± 0.08 0.104
 Cerebrovascular disease 0.20 ± 0.11 vs. 0.19 ± 0.08 0.305
 Active liver disease 0.18 ± 0.09 vs. 0.19 ± 0.08 0.240
 Cancer 0.18 ± 0.08 vs. 0.19 ± 0.08 0.080
Medication use (yes vs. no)
 ACEI/ARB 0.19 ± 0.10 vs. 0.19 ± 0.08 0.186
β-Adrenergic blocker 0.20 ± 0.10 vs. 0.19 ± 0.08 0.027
 Calcium channel blocker 0.22 ± 0.12 vs. 0.19 ± 0.08 <0.001
 Diuretics 0.20 ± 0.10 vs. 0.19 ± 0.08 0.315
 Other antihypertensives 0.22 ± 0.10 vs. 0.19 ± 0.08 0.002

Abbreviations: ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker; sUCr/Osm: spot urine creatinine-to-osmolality ratio. aAs indicated, a comparison for the means among the various ethnic groups is performed using the one-way analysis of variance (ANOVA) along with the Bonferroni method as the post hoc test.